Axovant tips nelotanserin from small molecule R&D Axovant has stopped nelotanserin development after it missed the primary endpoint in a phase 2 trial in patients with Lewy body dementia. The dull data compelled Axovant to miss the drug and finish its pivot from small molecules to gene therapies. The parent comp...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.